• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

EXTEND-IA TNK: Tenecteplase is superior to alteplase as neoadjuvant treatment for mechanical thrombectomy

byIyas DaghlasandDayton McMillan
October 29, 2018
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. When treated with tenecteplase, stroke patients eligible for mechanical thrombectomy had higher rates of reperfusion and superior clinical outcomes at 90 days relative to patients treated with alteplase.

2. There was no evidence that rates of intracerebral hemorrhage were different between the tenecteplase and alteplase groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recombinant tissue plasminogen activator, given as alteplase, has for many years been a cornerstone of acute stroke treatment. These patients often receive alteplase, a recombinant tissue plasminogen activator (tPA), prior to thrombectomy. Tenecteplase is another recombinant tPA that has greater specificity for fibrin and a longer half-life. It is unclear which recombinant tPA is superior as bridging therapy prior to mechanical thrombectomy.

This randomized controlled trial enrolled patients with large vessel stroke eligible to undergo thrombectomy and randomized them to pretreatment with tenecteplase or alteplase. The primary outcome was a predetermined degree of reperfusion. A key secondary outcome was clinical outcome assessed by the modified Rankin scale. The investigators found that patients receiving tenecteplase had higher rates of the tissue reperfusion and higher modified Rankin scale scores at 90 days.

Strengths of the study include its randomized, multicenter design. The use of a surrogate outcome as the primary outcome in the study is a weakness, as it may not translate to meaningful clinical outcomes. Furthermore, the trial was powered for noninferiority rather than superiority. Overall, these results support consideration for use of tenecteplase rather than alteplase prior to endovascular thrombectomy.

RELATED REPORTS

Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

Delayed alteplase has clinical benefits in posterior circulation stroke outcomes

Click to read the study, published in NEJM

Relevant Reading: Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

In-Depth [randomized controlled trial]: This was a phase three, multicenter, blinded randomized controlled trial that enrolled 202 patients (n = 101 in alteplase and tenecteplase groups) between 2015 and 2017 to compare outcomes amongst patients treated with either alteplase or tenecteplase prior to mechanical thrombectomy. Key inclusion criteria included onset of symptoms within 4.5 hours and large-vessel occlusion of either the internal carotid, middle cerebral, or basilar artery. There was no restriction by NIH stroke scale score, but patients with preexisting disability per the modified Rankin scale score were excluded. The primary outcome was reperfusion of greater than 50% of the involved ischemic territory, or absence of thrombus during angiography. Secondary outcomes included score at 90 days on the modified Rankin scale, and early improvement in National Institutes of Health Stroke Scale score (NIHSS) at 24 and 72 hours.

The primary outcome occurred in 22% of tenecteplase and 10% of alteplase patients, respectively. The study arm was noninferior (P = 0.002) and superior (P = 0.02) to the comparator group (adjusted odds ratio [aOR], 2.6; 95% confidence interval [CI], 1.1 to 5.9). The median modified Rankin scale score was was 2 in the tenecteplase group, and 3 in the alteplase group (odds ration [OR], 1.7; 95% CI, 1.0 to 2.8; P = 0.04). Evidence of early neurologic improvement (within 24 or 72 hours) did not meet the threshold or statistical significance (P24 = 0.06, P72 = 0.053). One patient in both the tenecteplase and alteplase group had a symptomatic intracerebral hemorrhage.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: endovascular thrombectomyischemic strokethrombolysis
Previous Post

In-utero exposure to tenofovir-emtricitabine not associated with higher risk of adverse birth outcomes

Next Post

Hospital readmissions occurring within 7 days post-discharge may be more preventable than later readmissions

RelatedReports

Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation

July 4, 2025
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Chronic Disease

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

June 4, 2025
Stroke expansion following intra-arterial therapy may explain worse outcomes
Emergency

Delayed alteplase has clinical benefits in posterior circulation stroke outcomes

May 30, 2025
Use of aspirin for primary prevention linked to increased risk of intracranial hemorrhage
Cardiology

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

May 2, 2025
Next Post
HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

Hospital readmissions occurring within 7 days post-discharge may be more preventable than later readmissions

Screening insufficient for newborns exposed to hepatitis C virus

Screening insufficient for newborns exposed to hepatitis C virus

Reduced gestational weight gain with lifestyle intervention

Improved research methods needed to determine effectiveness of anti-obesity public health initiatives

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.